Pioglitazone and Bladder Cancer

The medical arena has been abuzz for a few weeks now following revelations that the drug Pioglitazone might cause cancer. Pioglitazone (the trade name is Actos) is a very common drug used to help control blood sugar levels among individuals suffering from type 2 diabetes.

actos order onlineHowever, according to recent research, the use of the drug can bring about a 63 percent increase in the risk of bladder cancer.

According to the Health and Social Care Information Center, a UK organization, there were over a million prescriptions of Pioglitazone hydrochloride dispensed in the country in 2015 alone.

According to Doctor Laurent Azoulay, the lead author from the Center for Clinical Epidemiology, Montreal, Quebec, Canada, the study that was carried out encompassed a relatively large population, with the results that associated the use of the drug with an increase in the risk of bladder cancer proving quite difficult to oppose.Actos (Pioglitazone)

Questions about the drug first arose in 2005 after a number of individuals that were taking the drug in a trial at the time manifested bladder cancer. Numerous reports have since come out, delivering very contradictory findings on the subject.

Researchers from the most recent study analyzed nearly one hundred and fifty thousand patients from the UK Clinical Practice Research Database that were newly treated with anti-diabetic drugs between the years of 2000 and 2014, discovering that over 600 of these patients had been diagnosed with bladder cancer.

According to the Canadian team that carried out the research, the risk of bladder cancer spiked with an increase in the use of Pioglitazone. With the study making an effort to compare the figures related to Pioglitazone with data regarding other anti-diabetic drugs, the research team determined that Rosiglitazone did not increase the risk of cancer manifestation; this despite the drug having been removed from shelves in 2010 because it increased the risk of cardiovascular disorders.

The issue of Pioglitazone matters because type 2 diabetes affects an estimated 3 million people in England and Wales. Of the over 10,000 people that are diagnosed with bladder cancer on an annual basis, an estimated 5,000 people die from the ailment.

The Canadian research team believes that diabetes patients should be informed about the risks that Pioglitazone poses, giving them a choice to either continue using the drug or to abandon it all together.

The anti-diabetes drug arena is a minefield. A number of the most popular anti-diabetic drugs have been linked to one of the several dangerous illnesses, while diabetes patients are struggling to find an effective means of combating the ailment without facing unexpected side effects.

Back to Top